SCHEMBL30075860

SCHEMBL30075860

C=CS(=O)(=O)CC1CN(C(=O)OCCCC)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ATM Q13315 1/20 0.36
▸ GBA2 Q9HCG7 1/20 0.35
▸ CHRM2 P08172 2/20 0.35
▸ CHRM1 P11229 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ HCAR2 Q8TDS4 1/20 0.33
▸ HRH2 P25021 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ MMP13 P45452 3/20 0.32
▸ MMP3 P08254 2/20 0.32
▸ MMP9 P14780 2/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP8 P22894 1/20 0.32
▸ BCHE P06276 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30075700 0.83 LMNA (0.48) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL30075837 0.80 LMNA (0.44) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL30075784 0.78 LMNA (0.43) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL4968751 0.76 LMNA (0.53) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL4968757 0.76 LMNA (0.53) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL23579314 0.76 NR1H2 (0.49) SMN1; SMN2HPGDALDH1A1GPR119
SCHEMBL30711555 0.76 LMNA (0.49) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL30129908 0.75 LMNA (0.51) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL30129902 0.75 LMNA (0.51) LMNAPOLBSMN1; SMN2HPGDTSHR
SCHEMBL30241901 0.75 SMN1; SMN2 (0.46) LMNAPOLBSMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081515-A1 INHIBITORS OF MUTANT FORMS OF EGFR Blueprint Medicines Corporation (US) 2022-11-02 — — EP disclosed
Send feedback